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OBJECTIVE: To examine the responsiveness to change of the
Spanish version of the Juniper Mini Asthma Quality of Life
Questionnaire (Mini-AQLQ). METHODS: 253 patients with
mild to moderate uncontrolled asthma (patients with sympto-
matology and/or need for short-acting ƒ≤2-agonists) were
included in the study (61% women, mean age 36 years). A full
history and physical examination were performed and mon-
telukast was added at the baseline visit. All subjects completed
the Mini-AQLQ questionnaire twice: at recruitment and after
two months. Differences in patient scores before and after the
montelukast addition were analysed using paired t-test. Respon-
siveness was assessed by calculating the standardized effect size
(SES). A within-subject change in score of 0.5 is deﬁned as the
minimal clinically important difference (MCID). RESULTS: The
Mini-AQLQ was responsive to changes over a two-month
period. All Mini-AQLQ global and domain scores signiﬁcantly
improved after montelukast addition (p < 0.01 for all compar-
isons). Mini-AQLQ score changes were signiﬁcantly different for
patients who improved and those that remained stable or dete-
riorated (p < 0.001). The global score effect size was 0.91,
ranging from 0.5 to 1.0 for the domains. The percentage of
patients with mild and moderate asthma who were considered
to have experienced a MCID in global score was 57.5% and
71.4% respectively, with average baseline scores of 5.0 and 4.3
respectively. The domain that experienced the greatest number
of patients experiencing a clinically important improvement was
Symptoms, with 65% and 78% of patients with mild and mod-
erate asthma respectively. CONCLUSIONS: The Spanish version
of the Mini-AQLQ is suitable for use in longitudinal studies
where it is appropriate to assess the impact of asthma on the
quality of life of individual patients with mild to moderate
asthma. A high proportion of patients experienced a clinically
meaningful improvement in their Quality of Life after addition
of montelukast to their asthma therapy.
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OBJECTIVE: To undertake cost-effectiveness evaluation of
pemetrexed/cisplatin (pem/cis) compared to cisplatin (cis) for
patients with advanced malignant pleural mesothelioma (MPM)
in Scotland. METHOD: The efﬁcacy of pem/cis versus cis was
evaluated in the ﬁrst randomised phase III trial in patients with
unresectable MPM (Vogelzang 2003). Emergent data early in the
trial led to patients being fully supplemented with folic acid and
vitamin B12. Survival beneﬁt was assessed in fully vitamin-sup-
plemented patients with advanced disease [FS (stage III/IV)]. A
cost/life-year saved (LYS) analysis of FS (stage III/IV) cohort
using the median survival gain from the clinical trial was under-
taken. This cohort was chosen because it represented the most
realistic use of pemetrexed in Scottish clinical practice: most
MPM patients in Scotland have advanced disease at presentation
(Aziz 2002) and vitamin supplementation is mandatory with
pemetrexed treatment (ALIMTA SPC). Speciﬁc unit costs were
applied to drug acquisition, administration, supportive care med-
ication, hospitalisations for serious adverse events and post-
study chemotherapy, with incidence derived directly from the
clinical trial. A discount rate of 3.5% per annum was applied to
all outcomes. RESULTS: The survival of pem/cis over cisplatin
in this cohort was 13.2 versus 8.4 months (p = 0.003; HR 0.63
[95%CI 0.46–0.86]). The incremental per patient cost for
pem/cis compared to cis was £8196. The incremental cost/LYS
for this cohort is £20,844. The robustness of the model was
tested using one-way sensitivity analyses on key variables affect-
ing both cost and outcomes estimates in the cost-effectiveness
model. Little variation in the incremental cost/LYS was found
with the variables tested for the FS with advanced disease
patients (£17,500–£25,000). CONCLUSIONS: The trial demon-
strated clear survival gain for the cohort of fully supplemented
pem/cis patients with advanced disease. This analysis demon-
strates that the combination may be considered a cost-effective
treatment for patients with advanced MPM.
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OBJECTIVES: Historical evaluations of patients in clinical trials
suggest that patients with advanced nonsmall cell lung cancer
(NSCLC) treated with chemotherapy can expect a two-week
improvement of median survival. We postulated that, with the
publication of randomized trials showing survival improve-
ments, this apparent gain might be attributable to lead time
effects; that is, patients being treated earlier in the natural history
of their disease. METHODS: Patients with Stage IIIb and IV
nonsmall lung cancer were identiﬁed from the SEER-Medicare
database, and population-based cancer registry linked to
Medicare claims. Survival for consecutive cohorts diagnosed
between 1994 and 1999 was analyzed to determine differences
from time of diagnosis to time of treatment and for overall time
from diagnosis to death. RESULTS: During this period 11,995
patients were diagnosed with stages IIIB and IV NSCLC. The
mean age was 75 years, 57% were males and distribution by race
was: 82.4% white, 9.4% African Americans, 3.2% Asian, 1.2%
Hispanic, and 3.7% others. 30% were treated with chemother-
apy. The mean time to chemotherapy initiation in 1994 was 1.63
months while in 1999 was 1.34 (p = 0.0004). This change rep-
resents a difference in treatment initiation of 8.7 days, or almost
62% of the survival beneﬁt observed in the historical clinical trial
evaluation covering 25 years. CONCLUSIONS: Over time there
has been a trend towards earlier initiation of chemotherapy 
following diagnosis in advanced NSCLC. If the date from
chemotherapy initiation is used as a starting point for survival
analyses, as is frequently the case, researchers might erroneously
conclude that survival is improving due to treatment, when in
fact much of the apparent gains are simply due to patients receiv-
ing treatment earlier in the history of their disease.
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OBJECTIVES: To evaluate the economic impact of the intro-
duction in the French market in 2003 of the new agent Aprepi-
tant for the prevention of acute and delayed nausea and vomiting
associated with Highly Emetogenic cisplatine-based cancer
